Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...

New findings from a major trial offer a clearer, more nuanced view of how GLP-1 medications may influence the course of ...

Global diabetes drug Ozempic (semaglutide) has now been launched in India by Danish pharmaceutical major Novo Nordisk. In an exclusive interaction with NDTV, Managing Director of Novo Nordisk India, ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...

There’s trouble brewing beneath the GLP-1 buzz. As Americans embrace blockbuster weight-loss drugs like Ozempic and Wegovy in ...

Danish pharmaceutical giant Novo Nordisk has introduced its type 2 diabetes treatment, Ozempic, in India. Positioned as a ...

Dozens of units of counterfeit Ozempic (semaglutide 1mg injection) were seized by the FDA, according to a drug safety alert issued by the Agency.

A peripherally acting cannabinoid receptor 1 antibody combined with semaglutide induced significant weight loss for adults ...

Adjunctive treatment with the GLP-1 agonist semaglutide significantly reduces the antipsychotic-related cardiometabolic risk ...

Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...

FDA may expedite approval timeline for Eli Lilly's weight-loss treatment, potentially moving decision date to late March from ...